Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | XIAP | P98170 | 1/20 | 0.62 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.62 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.57 |
| ▸ | LAP3 | P28838 | 7/20 | 0.56 |
| ▸ | ANPEP | P15144 | 2/20 | 0.56 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.56 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | CPA3 | P15088 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7415433 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL244193 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7436847 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7698421 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL5491058 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL2201323 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL2029167 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL650855 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL1309497 | 0.98 | ALPI (0.60) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL3688220 | 0.98 | ALPI (0.60) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0778827-B1 | PROCESS FOR PRODUCING A BETA-AMINO ALCOHOL | DEGUSSA (DE) | 2001-12-12 | — | — | EP | claimed |
| US-5994555-A | (4S,5S)-4-BENZYL-2-OXO-OXAZOLIDINE-5-CARBOXYLIC ACID FROM PHENYLALANINE AND PHTHALIC ANHYDRIDE | F. HOFFMAN-LAROCHE AG (CH) | 1999-11-30 | — | — | US | claimed |
| US-5859248-A | Process for the production of a β-amino alcohol | F. HOFFMAN-LA ROCHE AG (CH) | 1999-01-12 | — | — | US | claimed |
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | OSAKA CITY UNIVERSITY (JP) | 2023-12-19 | — | — | US | disclosed |
| EP-3466421-B1 | COMPOSITION FOR THE TREATMENT OF PERIPHERAL NERVE DISORDERS | UNIV OSAKA CITY (JP) | 2022-11-30 | — | — | EP | disclosed |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | OSAKA CITY UNIVERSITY (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190270770-A1 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | LANDSTEINER GENMED S L | 2019-09-05 | — | — | US | disclosed |
| US-10294269-B2 | Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation | LANDSTEINER GENMED, S.L. (ES) | 2019-05-21 | — | — | US | disclosed |
| EP-3466421-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | Osaka City University (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-3191112-B1 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | LANDSTEINER GENMED S L (ES) | 2019-03-20 | — | — | EP | disclosed |
| EP-2647386-B1 | LISSENCEPHALY THERAPEUTIC AGENT | UNIV OSAKA CITY (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-6329502-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS; TREATMENT OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | JAPAN ENERGY CORPORATION (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6313094-B1 | COMPOSITION FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | JAPAN ENERGY CORPORATION (JP) | 2001-11-06 | — | — | US | disclosed |
| US-6063955-A | OXIDIZING A THREO OR THREO-ERYTHRO-3-AMINO-2-HYDROXYBUTYRIC ACID ESTER, OPTICALLY ACTIVE AT 3-POSITION TO PRODUCE AN OPTICALLY ACTIVE 3-AMINO-2-OXOBUTYRIC ESTER, REDUCING ERYTHRO-SELECTIVELY CARBONYL GROUP AT 2-POSITION | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2000-05-16 | — | — | US | disclosed |
| CN-1245486-A | Ketobenzamides as calpain inhibitors | BASF AG (DE) | 2000-02-23 | — | — | CN | disclosed |
| US-5994555-A | (4S,5S)-4-BENZYL-2-OXO-OXAZOLIDINE-5-CARBOXYLIC ACID FROM PHENYLALANINE AND PHTHALIC ANHYDRIDE | F. HOFFMAN-LAROCHE AG (CH) | 1999-11-30 | — | — | US | disclosed |
| EP-0934923-A1 | OPTICALLY ACTIVE ERYTHRO-3-AMINO-2-HYDROXYBUTYRIC ESTERS AND PROCESS FOR PREPARING SAID ESTERS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1999-08-11 | — | — | EP | disclosed |
| EP-0490667-B1 | HIV protease inhibitors | JAPAN ENERGY CORP (JP) | 1999-06-09 | — | — | EP | disclosed |
| US-5859248-A | Process for the production of a β-amino alcohol | F. HOFFMAN-LA ROCHE AG (CH) | 1999-01-12 | — | — | US | disclosed |
| EP-0490667-A2 | HIV protease inhibitors | JAPAN ENERGY CORPORATION (JP) | 1992-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | PMP22, PRPH, NGF | ALPI 2951/4885PKM 562/4885PTGS1 487/4885 |
| US-10294269-B2 | Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation | DPP4, DPP3, DPP8 | ALPI 533/4885PKM 180/4885PTGS1 2086/4885 |
| US-20190270770-A1 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | DPP4, DPP3, DPP8 | ALPI 533/4885PKM 180/4885PTGS1 2086/4885 |
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | PMP22, PRPH, NGF | ALPI 2951/4885PKM 562/4885PTGS1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.